IRIS
TESTA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.108
AS - Asia 912
NA - Nord America 573
SA - Sud America 83
AF - Africa 9
Totale 11.685
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.959
US - Stati Uniti d'America 521
SG - Singapore 399
CN - Cina 232
VN - Vietnam 145
FR - Francia 77
BD - Bangladesh 57
BR - Brasile 51
HK - Hong Kong 24
AR - Argentina 18
CA - Canada 18
DE - Germania 14
CH - Svizzera 13
MX - Messico 13
JP - Giappone 11
FI - Finlandia 10
GB - Regno Unito 8
ID - Indonesia 8
IN - India 7
JM - Giamaica 6
EC - Ecuador 5
PK - Pakistan 5
CR - Costa Rica 4
ES - Italia 4
IQ - Iraq 4
PL - Polonia 4
SA - Arabia Saudita 4
ZA - Sudafrica 4
NP - Nepal 3
PS - Palestinian Territory 3
RU - Federazione Russa 3
SV - El Salvador 3
UA - Ucraina 3
UZ - Uzbekistan 3
VE - Venezuela 3
CL - Cile 2
CO - Colombia 2
GT - Guatemala 2
IE - Irlanda 2
KR - Corea 2
NL - Olanda 2
PR - Porto Rico 2
SE - Svezia 2
SK - Slovacchia (Repubblica Slovacca) 2
AZ - Azerbaigian 1
CG - Congo 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HN - Honduras 1
IR - Iran 1
KG - Kirghizistan 1
LT - Lituania 1
MA - Marocco 1
MM - Myanmar 1
NI - Nicaragua 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
TN - Tunisia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 11.685
Salva come PNG Salva come JPEG
Città #
Genova 6.578
Genoa 1.870
Rapallo 870
Vado Ligure 589
San Jose 194
Singapore 181
Lauterbourg 74
Ho Chi Minh City 45
Ashburn 43
Beijing 34
New York 27
Hanoi 24
Hong Kong 23
Santa Clara 17
Bordighera 16
Los Angeles 13
Frankfurt am Main 12
Zurich 12
Helsinki 10
Rome 9
Mexico City 8
Tianjin 8
Tokyo 8
Chicago 7
Des Moines 6
Orem 6
Atlanta 5
Kingston 5
São Paulo 5
Da Nang 4
Dallas 4
Haiphong 4
Milan 4
Shanghai 4
Buffalo 3
Charlotte 3
Houston 3
Jacksonville 3
Naples 3
Phoenix 3
Quito 3
Quảng Ngãi 3
San Francisco 3
Santo André 3
Vĩnh Long 3
Warsaw 3
Boston 2
Brampton 2
Brooklyn 2
Cape Town 2
Cardiff 2
Changsha 2
City of London 2
Clarksville 2
Denver 2
Dhaka 2
Dublin 2
Federal Way 2
Flores da Cunha 2
Francisco Morato 2
Guangzhou 2
Guatemala City 2
Gujranwala 2
Highland 2
Hải Dương 2
Jakarta 2
Johannesburg 2
Kathmandu 2
Lancaster 2
Las Vegas 2
Manlius 2
Memphis 2
Natal 2
Peoria 2
Philadelphia 2
Pisa 2
Pomona 2
Providence 2
Queens 2
Recife 2
Richmond 2
Rio de Janeiro 2
Riyadh 2
San Antonio 2
San José 2
San Salvador 2
Stockholm 2
Stone Mountain 2
Tashkent 2
Thái Bình 2
Virginia Beach 2
Việt Trì 2
Wilmington 2
Abidjan 1
Agadir 1
Alajuela 1
Algiers 1
Almendralejo 1
Alvorada 1
Amsterdam 1
Totale 10.856
Salva come PNG Salva come JPEG
Nome #
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 224
13C -Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. 217
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C 208
13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease 207
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice 195
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 195
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 189
. Liver iron accumulation in chronic hepatittis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. 186
Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis 179
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 176
Splanchnic haemodynamic effects of ketanserin in anaesthetized cirrhotic rats. 174
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? 170
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma 164
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 163
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 162
High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: Relationship with TNF-alpha levels 161
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. 160
Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats 160
Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. 158
Is there a role for multiple quantitative liver function tests? 157
Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. 157
13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis 156
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study 155
Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 155
Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C 148
Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"? 147
Influence of 1-week helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test 146
Liver enzyme alteration: a guide for clinicians 146
Propranolol reduces the response of serum bile acids to oral chenodeoxycholic acid, possibly as a reflex reaction to reduced portal blood flow in healthy and cirrhotic subjects. 145
Tryglycylvasopressin-reduced portal and systemic concentrations of serum bile acids after exogenous chenodeoxycholic acid load in rats as a reflection of reduced splanchnic blood flow 143
Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green 142
Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment 141
HOMA, BMI, and serum leptin levels variations during antiviral treatment suggest virus-related insulin resistance in noncirrhotic, nonobese, and nondiabetic chronic hepatitis C genotype 1 patients 140
Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study 139
Can changing counseling strategy change the picture of the chronic hepatitis C patient population? 139
Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? 138
The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis 138
Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis 138
The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis 137
Is aspartate aminotransferase enough? 135
Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C 135
Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients 135
Two or more synchronous combination of noninvasive test to increase accuracy of liver fibrosis in chronic hepatitis C. 134
Caffeine clearance in subjects with constitutional un conjugated hyperbilirubinemia 133
Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? 132
Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma 128
Histological determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C 128
Analysis of circadian fluctuations of bile salt concentration and pH in the stomach of normal subjects and patients suspected of having duodenogastric reflux. 128
Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C 127
Formation kinetics of the lidocaine metabolite (MEGX) in patients with chronic active hepatitis and cirrhosis 127
Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people 126
Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have? 124
Progressive liver functional impairment is associated with an increase in AST/ALT ratio 124
Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients 123
Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. 123
Chronic liver disease related to hepatitis C virus: age of patients seems to be a determinant of severity independently of viral genotype 122
Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. 122
Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis 119
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis 117
Proposal and Validation of the AST/ALT ratio for predicting the presence of significant fibrosis in patients with chronic hepatitis C. 117
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 117
Biochemical scores could reflect histological activity in chronic hepatitis C 116
Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. 113
Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage 112
Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection 108
Effects of the association of lansoprazole, clarithromycin and metronidazole for Helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. 105
13C-breath tests and liver fibrosis. 105
The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. 105
Wilson's disease with concomitant beta thalassaemia and factor V deficiency. 104
Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastroesophageal reflux disease. 102
Serum prolyl-hydroxylase as an index of fibrogenic activity in chronic active hepatitis and cirrhosis 101
Non-invasive assessment of liver function: trying not to miss an opportunity. 100
Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease 100
Oral or intravenous lidocaine administration to perform megx test? 98
Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. 98
Omeprazole decreased formation of monoethylglycinexylidide in a patient with chronic active hepatitis. 97
Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients 96
Probability of non-response during interferon therapy in patients with chronic hepatitis C 95
Inclusion of serum bile acids in Child-Turcotte-Pugh's score can improve grading assessment of alcoholic cirrhosis. 92
Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. 92
Postprandial serum bile acids after ursodeoxycholic acid. A possible test of intestinal absorption? 91
Plasma aminoacid ratios in alcoholic cirrhotics with subclinical encephalopathy: relationships with cerebral blood flow. 88
The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. 87
Malattie epatiche congenite 82
Serum bile acid profiles after endogenous and exogenous loads of bile acid into the enterohepatic circulation of healthy subjects and patiens with chronic liver disease. 81
Long-term follow-up of chronic hepatitis C patients after interferon alpha treatment: a clinical and functional study 76
Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. 63
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 58
Totale 11.696
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.828
article - articoli 36.936
book - libri 0
conference - conferenze 327
curatela - curatele 0
other - altro 287
patent - brevetti 0
selected - selezionate 0
volume - volumi 278
Totale 75.656
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.087 17 134 89 94 24 39 77 304 29 91 58 131
2022/20231.042 101 62 7 84 195 176 1 83 140 2 181 10
2023/2024408 18 68 8 57 35 48 13 29 14 5 43 70
2024/20251.349 50 112 39 76 195 150 100 245 51 52 111 168
2025/20262.138 281 30 113 181 288 262 408 105 99 185 84 102
2026/2027169 169 0 0 0 0 0 0 0 0 0 0 0
Totale 11.696